Free tool
FAERS Monitor: Enjaymo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761164 or its brand name (Enjaymo, Sutimlimab-Jome). Reports on generic versions are filed under their own applications.
Reports
321
Serious
180
56% of reports
Hospitalization
71
Death reported
54
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use39
- haemoglobin decreased23
- arthralgia20
- fatigue18
- death16
- haemolysis16
- condition aggravated15
- drug ineffective13
- headache13
- covid-1912
- cyanosis11
- nausea11
- inappropriate schedule of product administration10
- pain10
- dyspnoea9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 34 |
| 2023 | 59 |
| 2024 | 73 |
| 2025 | 72 |
| 2026 | 83 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,838 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| haemolysisSignal | 16 | 136.0 | 84.3 | 2,008 |
| cyanosisSignal | 11 | 45.9 | 25.7 | 439 |
| haemoglobin decreasedSignal | 23 | 14.7 | 9.9 | 281 |
| covid-19Signal | 12 | 4.5 | 2.6 | 29 |
| inappropriate schedule of product administrationSignal | 10 | 3.6 | 2.0 | 17 |
| condition aggravatedSignal | 15 | 3.2 | 2.0 | 21 |
| arthralgiaSignal | 20 | 3.2 | 2.1 | 28 |
| off label useSignal | 39 | 2.9 | 2.2 | 49 |
| fatigue | 18 | 1.5 | 1.0 | 3 |
| headache | 13 | 1.4 | 0.8 | 1 |
| death | 16 | 1.2 | 0.8 | 0 |
| pain | 10 | 1.1 | 0.6 | 0 |
| dyspnoea | 9 | 1.0 | 0.5 | 0 |
| nausea | 11 | 0.9 | 0.5 | 0 |
| drug ineffective | 13 | 0.6 | 0.4 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.